Small intestinal bacterial overgrowth in children with intestinal failure on home parenteral nutrition

Kathleen H McGrath, James Pitt, Julie E Bines, Kathleen H McGrath, James Pitt, Julie E Bines

Abstract

Background and aim: Children with intestinal failure (IF) have abnormal intestinal anatomy, secretion, or motility, which impairs homeostatic mechanisms and can lead to small intestinal bacterial overgrowth (SIBO). We sought to describe clinical features at the time of clinically suspected SIBO by experienced clinicians in children with IF on home parenteral nutrition (PN), review specific challenges of diagnostic testing in this population, and describe potential new diagnostic surrogate markers.

Methods: A descriptive single-center retrospective chart review was performed during all episodes of clinically suspected SIBO over 33 months. Information was recorded on clinical symptoms, and diagnostic tests performed.

Results: Of all patients on home PN, 71% (12/17) had at least one episode of clinically suspected SIBO (mean 1 episode/year, range 1-7); 50% of patients had short bowel syndrome (SBS), and 50% had non-SBS IF. The average reported symptoms per episode were 1.9 (range 1-5). Children with SBS reported fewer symptoms per episode (1.5) than children with non-SBS IF (2.3). Diarrhea was the most commonly reported symptom, particularly in children with SBS.

Conclusions: Children with IF on home PN are a high-risk group for SIBO. Clinical features of SIBO vary depending on the cause of IF and may mimic symptoms of the underlying condition. Diagnostic tests have innate challenges in this group, and a strong index of clinical suspicion is paramount. Further research is recommended into potential new surrogate markers (urinary metabolite screen, gastric aspirate) for this diagnostically challenging population.

Keywords: bacteria; child; diarrhea; parenteral nutrition, home; short bowel syndrome.

© 2019 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Figures

Figure 1
Figure 1
Frequency of reported clinical features at the time of clinically suspected SIBO in children with intestinal failure on home parenteral nutrition.

References

    1. Ghoshal UC, Ghoshal U. Small intestinal bacterial overgrowth and other intestinal disorders. Gastroenterol. Clin. North Am. 2017; 46: 103–20.
    1. Sieczkowska A, Landowski P, Kaminska B, Lifschitz C. Small bowel bacterial overgrowth in children. J. Pediatr. Gastroenterol. Nutr. 2016; 62: 196–207.
    1. Donaldson RM. Normal bacterial population of the intestine and their relation to intestinal function. N. Engl. J. Med. 1964; 270: 938–45.
    1. Khoshini R, Dai S‐C, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig. Dis. Sci. 2008; 53: 1443–54.
    1. Gasbarrini A, Lauritano EC, Gabrielli M et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig. Dis. 2007; 25: 237–40.
    1. Grace E, Shaw C, Whelan K, Andreyev HJN. Review article: small intestinal bacterial overgrowth‐ prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment. Pharmacol. Ther. 2013; 38: 674–88.
    1. Gasbarrini A, Corazza GR, Gasbarrini G et al. 1st Rome H2‐Breath Testing Consensus Conference Working Group. Methodology and indications of H2‐breath testing in gastrointestinal diseases: The Rome Consensus Conference. Aliment. Pharmacol. Ther. 2009; 29(Suppl. 1): 1–49.
    1. Pimentel M. Breath testing for small intestinal bacterial overgrowth: should we bother? Am. J. Gastroenterol. 2016; 111: 307–8.
    1. Chalmers RA, Valman HB, Liberman MM. Measurement of 4‐hydroxyphenylacetic aciduria as a screening test for small‐bowel disease. Clin. Chem. 1979; 25: 1791–4.
    1. Haan E, Brown G, Bankier A et al. Severe illness caused by the products of bacterial metabolism in a child with short gut. Eur. J. Pediatr. 1985; 144: 63–5.
    1. Pollitt RJ, Fowler B, Sardharwalla IB, Edwards MA, Gray RG. Increased excretion of propan‐1,3‐diol and 3‐hydroxyproprionic acid apparently caused by abnormal bacterial metabolism in the gut. Clin. Chim. Acta. 1987; 169: 151–7.
    1. Wendel U, Bakkeren J, de Jong J, Bongaerts G. Glutaric aciduria mediated by gut bacteria. J. Inherit. Metab. Dis. 1995; 18: 358–9.
    1. Bala L, Ghoshal UC, Ghoshal U et al. Malabsorption syndrome with and without small intestinal bacterial overgrowth: a study on upper‐gut aspirate using 1H NMR spectroscopy. Magn. Reson. Med. 2006; 56: 738–44.
    1. Pereira‐fantini PM, Byars SG, Pitt J et al. Unravelling the metabolic impact of SBS‐associated microbial dysbiosis: Insights from the piglet short bowel syndrome model. Sci. Rep. 2017; 7: 43326 10.1038/srep43326.
    1. Stotzer PO, Brandberg A, Kilander AF. Diagnosis of small intestinal bacterial overgrowth in clinical praxis: a comparison of the culture of small bowel aspirate, duodenal biopsies and gastric aspirate. Hepatogastroenterology. 1998; 45: 1018–22.
    1. Rezaie A, Pimentel M, Rao S. How to test and treat small intestinal bacterial overgrowth: an evidence‐based approach. Curr. Gastroenterol. Rep. 2016; 18: 8.
    1. Gutierrez IM, Kang KH, Calvert CE et al. Risk factors for small bowel bacterial overgrowth and diagnostic yield of duodenal aspirates in children with intestinal failure: a retrospective review. J. Pediatr. Surg. 2012; 47: 1150–4.
    1. Cole CR, Frem JC, Schmotzer B et al. The rate of bloodstream infection is high in infants with short bowel syndrome: relationship with small bowel bacterial overgrowth, enteral feeding, and inflammatory and immune responses. J. Pediatr. 2010; 156: 941–7.
    1. Kaufman SS, Loseke CA, Lupo JV et al. Influence of bacterial overgrowth and intestinal inflammation on duration of parenteral nutrition in children with short bowel syndrome. J. Pediatr. 1997; 131: 356–61.
    1. Quigley EM, Querra R, Abu‐Shanab A, eds. The Enteric Flora in Intestinal Failure: Small Intestinal Bacterial Overgrowth and Gut‐Derived Sepsis. Melden: Blackwell Publishing, 2008.
    1. Engstrand LH, Wefer H, Nystrom N et al. Intestinal dysbiosis in children with short bowel syndrome is associated with impaired outcome. Microbiome. 2015; 3: 18.
    1. Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao SC. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and /or fungal overgrowth. Aliment. Pharmacol. Ther. 2013; 37: 1103–11.
    1. Siniewicz‐Luzenczyk K, Bik‐Gawin A, Zeman K, Bak‐Romaniszyn L. Small intestinal bacterial overgrowth syndrome in children. Prz Gastroenterol. 2015; 10: 28–32.
    1. Franco DL, Disbrow MB, Kahn A et al. Duodenal aspirates for small intestinal bacterial overgrowth: yield, PPIs, and outcomes after treatment at a tertiary academic medical center. Gastroenterol. Res. Pract. 2015; 2015: 971582.
    1. Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol. Hepatol. 2007; 3: 112–22.
    1. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin. Gastroenterol. Hepatol. 2010; 8: 505–8.
    1. Ratuapli SK, Ellington TG, O'Neill M‐T et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am. J. Gastroenterol. 2012; 107: 730–5.
    1. Rosen R, Amirault J, Liu H et al. Changes in gastric and lung microflora with acid suppression: acid suppression and bacterial growth. JAMA Pediatr. 2014; 168: 932–7.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅